Cognitive burden of anticholinergic medications in psychotic disorders

Posted

Patients with psychotic disorders are often treated with numerous medications, many of which have anticholinergic activity. We assessed cognition in relation to the cumulative anticholinergic burden of multiple drugs included in treatment regimens of participants from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

Clinically stable participants with schizophrenia (n = 206), schizoaffective disorder (n = 131), and psychotic bipolar disorder (n = 146) were examined. Anticholinergic properties of all scheduled drugs were quantified using the Anticholinergic Drug Scale (ADS). ADS scores were summed across individual drugs to create a total ADS burden score for each participant and examined in relation to the Brief Assessment of Cognition in Schizophrenia (BACS).

View the full article at Schizophrenia Research